Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Fineline Cube Apr 13, 2026
Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Fineline Cube Apr 13, 2026
Company Deals

Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio

Fineline Cube Apr 13, 2026
Company Deals

Oricell Therapeutics Raises $110M+ in Pre‑IPO Round – Accelerates Global Expansion of First‑in‑Class CAR‑T for Liver Cancer

Fineline Cube Apr 12, 2026
Company Deals

Gilead Exercises Option on Kymera’s KT-200 for $45M – Advances CDK2 Molecular Glue Degrader to IND-Enabling Studies

Fineline Cube Apr 12, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Duality Biologics Files NMPA Market Approval for DB-1303 HER2 ADC – Phase III Study Beats T-DM1 in Metastatic Breast Cancer

Fineline Cube Apr 12, 2026
Company Drug

Sino Biopharm Doses First Patient in Phase II Study of Kylo-11 – First-in-Class siRNA Targeting LPA for Cardiovascular Disease

Fineline Cube Apr 12, 2026
Company Deals

Innovent Biologics Partners with ImmVirX to Launch Clinical Study Combining Tyvyt and IVX037

Fineline Cube Feb 21, 2024

Innovent Biologics Inc. (HKG: 1801), based in China, has announced the signing of a clinical...

Company

Biogen Appoints Ding Weibo as Head of Asia-Pacific Region, Succeeding Francis Wan

Fineline Cube Feb 21, 2024

Biogen (NASDAQ: BIIB) has announced the appointment of Ding Weibo as the new head of...

Company Deals

Shenzhen Eureka Biotechnology Secures RMB 300 Million in Series B+ Funding for CGT Expansion

Fineline Cube Feb 21, 2024

Shenzhen Eureka Biotechnology Co., Ltd., a specialist in cell and gene therapy (CGT) based in...

Company Drug

Mabwell Bioscience Receives FDA Green Light for B7-H3 Targeting ADC 7MW3711

Fineline Cube Feb 20, 2024

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a biopharmaceutical company based in China, has announced...

Company Deals

BMS and Sichuan Biokin Commence Joint Development of EGFR/HER3-Targeted ADC

Fineline Cube Feb 20, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a Chinese pharmaceutical company, has announced that a...

Company Deals

Everest Medicines Terminates Agreement with Providence Therapeutics, Retains mRNA Rights

Fineline Cube Feb 20, 2024

Everest Medicines (HKG: 1952), a biopharmaceutical company based in China, has announced the termination of...

Company Drug

Jacobio Pharma Gets CDE Green Light for Phase III Study Combining Gleevec Inhibitors in NSCLC

Fineline Cube Feb 20, 2024

Jacobio Pharma (HKG: 1167), a China-based pharmaceutical company, has announced that it has received approval...

Company Drug

Neurophth Biotechnology Completes Enrollment and Dosing in US Clinical Study for ND4-LHON Gene Therapy

Fineline Cube Feb 20, 2024

Neurophth Biotechnology Ltd, a leading gene therapy specialist based in China, has announced the completion...

Company Deals

Biocytogen Pharmaceuticals Inks Antibody Evaluation Deal with Gilead Sciences

Fineline Cube Feb 20, 2024

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315), a China-based biopharmaceutical company, has announced an antibody...

Company Deals

Evopoint Biosciences Secures USD 97.2 Million in Series E Financing to Boost Clinical Trials and Commercialization

Fineline Cube Feb 20, 2024

Evopoint Biosciences Co., Ltd., a Suzhou-based biopharmaceutical company, has announced the successful completion of a...

Company Drug

Phanes Therapeutics’ PT886 Receives CDE Approval for Clinical Trials in Advanced Solid Tumors

Fineline Cube Feb 20, 2024

Sino-US biotechnology company Phanes Therapeutics Inc. has announced that it has received clinical trial approval...

Company Drug

ImmunoTech Biopharm Gets NMPA Green Light for Clinical Study of aT19 Injection for B-ALL

Fineline Cube Feb 20, 2024

ImmunoTech Biopharm Ltd (HKG: 6978), a specialist in chimeric antigen receptor T-cell (CAR-T) therapies based...

Policy / Regulatory

Beijing, Tianjin, and Hebei Release Draft Proposal for Updated Drug Clinical Trial Inspection Standards

Fineline Cube Feb 20, 2024

The medical products administration bureaus of Beijing, Tianjin, and Hebei province have released a draft...

Company Drug

AstraZeneca’s Tagrisso Wins Expanded FDA Approval for EGFR-mutated NSCLC

Fineline Cube Feb 20, 2024

UK pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has received a new indication approval from the...

Company Drug

Innovent Biologics’ IBI311 Achieves Primary Endpoint in Phase III Study for Thyroid Eye Disease

Fineline Cube Feb 20, 2024

Innovent Biologics Inc., (HKG: 1801), a biopharmaceutical company based in China, has announced that its...

Policy / Regulatory

China’s CDE Issues Guiding Principles for ADC Research and Evaluation

Fineline Cube Feb 20, 2024

China’s Center for Drug Evaluation (CDE) has issued a notification outlining the “Guiding Principles for...

Company Legal / IP Policy / Regulatory

GSK and Peers Respond to FTC Criticism, Withdraw Patent Listings from US Orange Book

Fineline Cube Feb 20, 2024

Three pharmaceutical companies, including the UK’s GSK (NYSE: GSK), have responded to the Federal Trade...

Company Deals

Astellas Pharma Partners with Kelonia Therapeutics to Advance CAR-T Cell Therapies

Fineline Cube Feb 19, 2024

Astellas Pharma Inc. (TYO: 4503) has announced a strategic research collaboration and licensing agreement with...

Company Drug

Denali Therapeutics Faces Setback as ALS Trial Fails to Meet Primary Endpoint

Fineline Cube Feb 19, 2024

Denali Therapeutics (NASDAQ: DNLI) has announced disappointing results from a Phase II trial of its...

Policy / Regulatory

China’s NMPA Releases 77th Batch of Reference Drugs for Generic Quality Evaluation

Fineline Cube Feb 19, 2024

The National Medical Products Administration (NMPA) has released the 77th batch of reference drugs for...

Posts pagination

1 … 383 384 385 … 649

Recent updates

  • Gaush Meditech Secures CE Mark for Corneal Confocal Microscope, Paving Way for EU Commercial Launch
  • Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets
  • Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech
  • Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology
  • Sun Pharma in Advanced Talks to Acquire Organon for $12 Billion, Bolstering Women’s Health Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Medical Device

Gaush Meditech Secures CE Mark for Corneal Confocal Microscope, Paving Way for EU Commercial Launch

Company Deals

Neurocrine Biosciences to Acquire Soleno Therapeutics for $2.9 Billion, Adding Three First-in-Class Commercial Assets

Others

Nanjing Pharma Launches $110M Corporate Fund to Acquire Controlling Stakes in Datsing Bio and Kejian Tech

Company Deals

Telix and Regeneron Forge $575M+ Radiopharmaceutical Alliance to Advance Precision Oncology

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.